Longboard Pharmaceuticals Reports Results for Bexicaserin (LP352) in P-Ib/IIa Trial for Developmental and Epileptic Encephalopathies (DEEs)
Shots:
- The P-Ib/IIa (PACIFIC) trial evaluates the safety, tolerability, efficacy & PK of Bexicaserin (6/9/12mg, TID) vs PBO in patients (n=52) aged 12 & 65yrs. with DEE (DS, LGS & other DEE) across 34 sites in the US & Australia. The 1EP includes median percent change from baseline in countable motor seizure frequency
- As per the results, the median number of countable motor seizures per 28-day period at baseline was 38.8 vs 20.8 & the median change from baseline depicted a decrease of 53.3% vs 20.8%
- Moreover, the median change in frequency in DS, LGS & DEE Other cohorts depicted a decrease of 72.1%, 48.1% & 61.2% respectively. Additionally, patients completing the (PACIFIC) trial were enrolled in the ongoing 52wks. open-label extension study
Ref: Longboard Pharmaceuticals | Image: Longboard Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
